• In July 2026, STAAR Surgical Company announced that net sales for the second quarter of 2026 are expected to exceed US$90,000,000, compared with US$44,300,000 in the same quarter of 2025.
• This updated guidance points to a very large year-on-year increase in quarterly revenue, suggesting meaningful business momentum and stronger demand for its implantable lenses.
• Given this sharply higher revenue guidance for the upcoming quarter, we'll now explore how it may reshape STAAR Surgical's investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

STAAR Surgical Investment Narrative Recap

To own STAAR Surgical, you need to believe implantable lenses can become a preferred vision correction option and that the company can convert that potential into sustainable, profitable growth. The sharply higher Q2 2026 revenue guidance reinforces the near term catalyst of a possible demand recovery, but it does not remove key risks around China exposure, distributor dependence, and refractive procedure volumes in weaker markets.

Among recent developments, the FDA’s February 2026 decision to expand the age indication for EVO and EVO+ ICLs from 21–45 to 21–60 years is especially relevant. This broadened label directly supports the revenue momentum implied in the new guidance by enlarging the eligible patient pool, but it also raises the stakes: any future slowdown in procedure growth or increased competition for this wider age group could weigh more heavily on results.

However, investors should also be aware that if refractive procedure growth in China and the Americas remains under pressure while STAAR leans more heavily on a single distributor model and extended payment terms...

STAAR Surgical's narrative projects $400.0 million revenue and $36.5 million earnings by 2029. This requires 11.3% yearly revenue growth and a $57.5 million earnings increase from -$21.0 million today.

Uncover how STAAR Surgical's forecasts yield a $29.67 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Before this guidance, the most pessimistic analysts expected revenue of about US$373 million and earnings of US$27 million by 2029, so this Q2 update may cause you to rethink how much weight you give to those harsher views versus the possibility that current revenue strength proves temporary.

Explore 2 other fair value estimates on STAAR Surgical - why the stock might be worth just $29.67!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your STAAR Surgical research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free STAAR Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate STAAR Surgical's overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.